在NSTEMI中使用Bivalirudin与Heparin:大型随机试验的个人患者数据元分析
Behnood Bikdeli1,2,3, David Erlinge4, Marco Valgimigli5
1Cardiovascular Medicine Division (B.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
在接受PCI的非ST段升高心肌梗塞患者中,比瓦利鲁丁和肝素的疗效相似. 与肝素相比,比瓦利鲁丁显著减少了严重出血事件.
科学领域:
- 心脏病学
- 药理学
背景情况:
- 在接受穿皮冠状动脉干预 (PCI) 的非ST段升高心肌梗塞 (NSTEMI) 患者中,比瓦利鲁丁与肝素抗凝剂的益处风险概况仍然不确定.
- 之前的元分析缺乏提供最终结论的细节性.
结论:
- 在接受PCI的NSTEMI患者中,使用比瓦利鲁丁或肝素进行的手术抗凝剂会产生可比的死亡率和缺血事件.
- 与肝素相比,比利鲁丁通过减少严重出血并发症显示出显著的安全优势.
更多相关视频
08:12Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
相关概念视频
Acute Coronary Syndrome I: Introduction
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
